Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Probability Laws01:49

Probability Laws

41.2K
Overview
41.2K
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

222
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
222
Strategies for Assessing and Addressing Confounding01:25

Strategies for Assessing and Addressing Confounding

136
Confounding is a critical issue in epidemiological studies, often leading to misleading conclusions about associations between exposures and outcomes. It occurs when the relationship between the exposure and the outcome is mixed with the effects of other factors that influence the outcome. Given that, addressing confounding is of high importance for drawing accurate inferences in research.
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
136
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

156
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
156
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

13.9K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
13.9K
Regression Toward the Mean01:52

Regression Toward the Mean

6.3K
Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Estimating Risk Differences Using Large Healthcare Data Networks for Medical Product Post-Market Safety Outcomes in a Distributed Data Setting and Allowing for Active Post-Market Surveillance.

Statistics in medicine·2026
Same author

Safety and pharmacodynamics of the ferroportin inhibitor vamifeport in patients with non-transfusion-dependent β-thalassemia: results from a randomized phase 2a study.

Orphanet journal of rare diseases·2025
Same author

Totality of evidence of the effectiveness of repurposed therapies for COVID-19: Can we use real-world studies alongside randomized controlled trials?

Clinical and translational science·2023
Same author

Platform trials to evaluate the benefit-risk of COVID-19 therapeutics: Successes, learnings, and recommendations for future pandemics.

Contemporary clinical trials·2023
Same author

On the use of non-concurrent controls in platform trials: a scoping review.

Trials·2023
Same author

A Tutorial on Modern Bayesian Methods in Clinical Trials.

Therapeutic innovation & regulatory science·2023

Related Experiment Video

Updated: Aug 16, 2025

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

13.8K

Bayesian Strategies in Rare Diseases.

Ursula Garczarek1, Natalia Muehlemann2, Frank Richard3

  • 1Cytel, Cambridge, MA, USA.

Therapeutic Innovation & Regulatory Science
|December 24, 2022
PubMed
Summary

Bayesian strategies offer innovative solutions for rare disease drug development, overcoming challenges like limited patient data and poor understanding of disease progression. These adaptive trial methods accelerate learning and integrate prior knowledge for better decision-making.

Keywords:
Adaptive designBayesian designClinical trialsDrug developmentRare diseases

More Related Videos

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
05:51

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia

Published on: June 15, 2011

25.9K
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

11.1K

Related Experiment Videos

Last Updated: Aug 16, 2025

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

13.8K
A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
05:51

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia

Published on: June 15, 2011

25.9K
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

11.1K

Area of Science:

  • Clinical Trial Design
  • Biostatistics
  • Drug Development

Background:

  • Rare disease drug development faces significant challenges, including poorly understood disease natural history and limited patient populations.
  • Standard clinical trial designs are often inadequate for generating sufficient safety and efficacy data in small patient groups.
  • Stakeholders seek innovative approaches to improve the efficiency and success rates of rare disease drug development.

Purpose of the Study:

  • To introduce and advocate for the use of Bayesian strategies in planning and analyzing clinical trials for rare diseases.
  • To support clinical decision-makers in selecting optimal drug development pathways using Bayesian methods.
  • To address barriers to Bayesian adoption, such as knowledge gaps and regulatory uncertainty.

Main Methods:

  • Utilizing Bayesian statistics to facilitate adaptive clinical trial designs with accelerated learning curves.
  • Implementing Bayesian approaches that allow for careful consideration, continuous monitoring, and updating of design choices.
  • Illustrating Bayesian concepts like borrowing, extrapolation, and modeling with practical examples developed with regulatory bodies.

Main Results:

  • Bayesian methods provide a principled framework for integrating prior clinical information with accumulating trial data.
  • Adaptive Bayesian trials enable efficient data collection and analysis, even with small patient numbers.
  • Demonstrated applicability of Bayesian strategies in rare disease contexts through regulatory-engaged examples.

Conclusions:

  • Bayesian strategies represent a viable and advantageous option for rare disease clinical trial planning and analysis.
  • These methods enhance decision-making by seamlessly combining prior knowledge with new data within a robust framework.
  • Addressing knowledge and regulatory guidance gaps can promote wider adoption of Bayesian approaches in rare disease drug development.